Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2018 Aug 31;13(8):e0203583. doi: 10.1371/journal.pone.0203583

Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

The PLOS ONE Staff
PMCID: PMC6118391  PMID: 30169544

S1 Table is omitted from the list of Supporting Information. It can be viewed below.

S1 File is also omitted from the list of Supporting Information. It can be viewed below.

The publisher apologizes for the errors.

Supporting information

S1 Table. Summary of inhibitors used in this study and the corresponding cellular transporters upon which they act.

(DOCX)

S1 File. Supplementary methods.

(DOCX)

Reference

  • 1.Eadie LN, Dang P, Goyne JM, Hughes TP, White DL (2018) ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE 13(1): e0192180 10.1371/journal.pone.0192180 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. Summary of inhibitors used in this study and the corresponding cellular transporters upon which they act.

(DOCX)

S1 File. Supplementary methods.

(DOCX)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES